ATLANTA, July 22, 2025 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed Alto Neuroscience, Inc. (“Alto” or the “Company”) (NYSE: ANRO). The lawsuit alleges that throughout the Class Period, and in the Company’s Offering Documents, Defendants made materially false and/or misleading statements and/or failed to disclose material adverse information concerning Alto’s business, operations, and prospects, including allegations that: (i) ALTO-100 was less effective in treating MDD than Defenda ...

Core Viewpoint - Genmab A/S (GMAB) shows potential for significant upside, with a mean price target of $30.36 indicating a 40% increase from the current price of $21.69 [1] Price Targets and Analyst Consensus - The average price target consists of seven estimates ranging from $20.00 to $46.00, with a standard deviation of $8.82, indicating variability among analysts [2] - The lowest estimate suggests a decline of 7.8%, while the highest points to a 112.1% upside [2] - A low standard deviation indicates strong agreement among analysts regarding the stock's price direction [9] Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism about GMAB's earnings prospects, as evidenced by upward revisions in EPS estimates [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 7.4%, with two estimates moving higher and one lower [12] - GMAB holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors [13] Caution on Price Targets - While price targets are often sought after, they can mislead investors, as empirical research shows they rarely indicate actual price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

NEW YORK, July 22, 2025 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Northern District of California on behalf of all persons or entities who purchased or otherwise acquired Alto Neuroscience, Inc. (“Alto Neuroscience” or the “Company”) (NYSE: ANRO) (i) between February 2, 2024 and October 22, 2024, inclusive (the “Class Period”); and/or (ii) pursuant and/or traceable to Alto Neuroscience’s registrat ...

Key Takeaways SRPT is pausing U.S. Elevidys shipments to complete safety labeling changes and respond to FDA requests. The move follows patient deaths linked to ALF in studies using the same AAVrh74 gene therapy vector. SRPT expects significant financial impact in quarters ahead as Elevidys drove over half of its Q1 revenues.Shares of Sarepta Therapeutics (SRPT) are declining in the pre-market hours today after the announcement that it will voluntarily and temporarily halt all U.S. shipments of Elevidys, ...

Group 1 - Lyell Immunopharma (NASDAQ: LYEL) has made significant progress with its CD19/CD20 CAR-T cell therapy targeting patients with aggressive 3rd-line + Large B-Cell Lymphoma (LBCL) [2] - The company is part of the Biotech Analysis Central service, which provides in-depth analysis of various pharmaceutical companies [2] Group 2 - The Biotech Analysis Central service includes a library of over 600 biotech investing articles and a model portfolio of more than 10 small and mid-cap stocks [2] - The service is available for $49 per month, with a yearly plan offering a 33.50% discount at $399 per year [1]

Danaher (DHR) Q2 2025 Earnings Call July 22, 2025 08:00 AM ET Company ParticipantsJohn Bedford - VP - IRRainer Blair - President & CEOMichael Ryskin - Managing DirectorDoug Schenkel - MD - Life Science Tools & DiagnosticsMatt McGrew - EVP & CFOScott Davis - Chairman, CEO & Founding Partner – Multi-Industry ResearchTycho Peterson - Managing Director, Global EquitiesVijay Kumar - Senior MDPuneet Souda - Senior MDConference Call ParticipantsDan Leonard - MD & Research AnalystDaniel Brennan - Senior Equity Rese ...

Danaher (DHR) Q2 2025 Earnings Call July 22, 2025 08:00 AM ET Speaker0My name is Margo, and I'll be your conference facilitator this morning. At this time, I'd like to welcome everyone to Danaher Corporation's Second Quarter twenty twenty five Earnings Results Conference Call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. I will now turn the call over to John Bedford, Vice President of Investor Relations.Mr. Bedf ...

NEW YORK, July 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Rocket Pharmaceuticals, Inc. ("Rocket" or the "Company") (NASDAQ: RCKT) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Rocket investors who were adversely affected by alleged securities fraud between February 27, 2025 and May 26, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/rocket-pharmaceuticals-i ...

SOUTH SAN FRANCISCO, Calif., July 22, 2025 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) (“Senti Bio”), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Senti Bio’s Co-Founder and Chief Executive Officer of Senti, participated in the Virtual Investor “What’s Your Story” Summer Spotlight On-Demand Conference. As part of the event, Dr. Lu dove deeper into his dedicat ...

NEW YORK, July 22, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Capricor Therapeutics, Inc. ("Capricor" or the "Company") (NASDAQ: CAPR) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Capricor investors who were adversely affected by alleged securities fraud between October 9, 2024 and July 10, 2025. Follow the link below to get more information and be contacted by a member of our team:https://zlk.com/pslra-1/capricor-therapeutics- ...